Evidence map›Paper›PMID 39722614›Full record

ReviewClinical and molecular hepatology2025

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment.

Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D Parikh, Ghassan K Abou-Alfa, Amit G Singal, Ju Dong Yang

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and molecular hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07417800 (Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning), which is not on this map. Cited by 213 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
213citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07417800 recruitingnot on this map

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

TypeobservationalSponsorSecond Affiliated Hospital, Zhejiang University, School of MedicineRan2025 to 2029Enrolled11,000ConditionsHepatocellular Carcinoma (HCC), Artificial Intelligent, Adjuvant Chemoradiotherapy, TACEArmsAI adjuvant therapy
3 · Its place in the literature

Who cites it

213 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

153 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Soo Young HwangDepartment of Internal Medicine, University of Maryland Medical Center, Midtown Campus, Baltimore, Maryland, USA.
Pojsakorn DanpanichkulDepartment of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Vatche AgopianDumont-UCLA Transplant and Liver Cancer Centers, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Neil MehtaDivision of Gastroenterology, Department of Medicine, University of California, San Francisco, California, USA.
Neehar D ParikhDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
Ghassan K Abou-AlfaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Amit G SingalDivision of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, Texas, USA.
Ju Dong YangKarsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Funding

Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinomaR01MD012565 · NIMHD · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT, YOPP, ADAM · 2018 to 2022
$4.3M
Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease OutcomesR01CA256977 · NCI · BAYLOR COLLEGE OF MEDICINE · PI KANWAL, FASIHA, SINGAL, AMIT · 2021 to 2025
$3.0M
Novel circulating biomarker digital scores for assessing treatment response in liver cancerK08CA259534 · NCI · CEDARS-SINAI MEDICAL CENTER · PI YANG, JU DONG · 2022 to 2024
$807k
AgenusArcusAstra ZenecaBioNtechBMSElicioGenentech/RocheHelsinnNCI NIH HHS K08 CA259534NCI NIH HHS K08CA259534NCI NIH HHS R01 CA256977NCI NIH HHS R01 MD012565NIMHD NIH HHS R01 MD012565Parker InstitutePertzyePumaQEDServierYiviva
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality. HCC due to chronic hepatitis B virus (HBV) or C virus (HCV) infection has decreased due to universal vaccination for HBV and effective antiviral therapy for both HBV and HCV, but HCC related to metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease is increasing. Biannual liver ultrasonography and serum α-fetoprotein are the primary surveillance tools for early HCC detection among high-risk patients (e.g., cirrhosis, chronic HBV). Alternative surveillance tools such as blood-based biomarker panels and abbreviated magnetic resonance imaging (MRI) are being investigated. Multiphasic computed tomography or MRI is the standard for HCC diagnosis, but histological confirmation should be considered, especially when inconclusive findings are seen on cross-sectional imaging. Staging and treatment decisions are complex and should be made in multidisciplinary settings, incorporating multiple factors including tumor burden, degree of liver dysfunction, patient performance status, available expertise, and patient preferences. Early-stage HCC is best treated with curative options such as resection, ablation, or transplantation. For intermediate-stage disease, locoregional therapies are primarily recommended although systemic therapies may be preferred for patients with large intrahepatic tumor burden. In advanced-stage disease, immune checkpoint inhibitor-based therapy is the preferred treatment regimen. In this review article, we discuss the recent global epidemiology, risk factors, and HCC care continuum encompassing surveillance, diagnosis, staging, and treatments.

Indexed as

Carcinoma, HepatocellularLiver Neoplasmsalpha-FetoproteinsHumansMagnetic Resonance ImagingNeoplasm Stagingalpha-FetoproteinsHepatocellular carcinomaLiver cirrhosisLiver diseasesLiver neoplasms

Identifiers

PMID39722614
PMCPMC11925437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.